A Phase-1, Parallel-Design, Open-Label, Randomized, Multiple-Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3549492 in Healthy Participants With Overweight or Obesity
Latest Information Update: 10 Dec 2025
At a glance
- Drugs Naperiglipron (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
Most Recent Events
- 26 Nov 2025 New trial record